Copenhagen Prospective Personalized Oncology (CoPPO)
CoPPO
A Prospective Study Using Genomic Screening to Select Patients for Targeted Molecular Treatment
1 other identifier
interventional
500
1 country
1
Brief Summary
Patients with advanced solid tumors referred to the Phase 1 Unit are offered mapping of GA for identification of pts who could benefit from a personalized treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started May 2013
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2013
CompletedFirst Submitted
Initial submission to the registry
October 8, 2014
CompletedFirst Posted
Study publicly available on registry
November 14, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2023
CompletedOctober 26, 2022
October 1, 2022
10.6 years
October 8, 2014
October 25, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Median progression free survival (PFS)
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Median time from date of randomization to date of progression or death, assessed up to 100 months
Study Arms (1)
tumor biopsy
EXPERIMENTALTumor biopsy for targeted treatment according to molecular profile
Interventions
Eligibility Criteria
You may qualify if:
- Solid tumor
- No standard treatment option
- PS 0-1
- Lesion assessable for biopsy
- Measurable disease
- Informed consent
You may not qualify if:
- Life expectancy \< 3 months
- Bone marrow suppression
- Abnormal renal or hepatic function
- Serious concurrent medical conditions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ulrik Lassenlead
Study Sites (1)
Rigshospitalet
Copenhagen, Denmark
Related Publications (2)
Jacobsen IC, Spanggaard I, Hojgaard M, Belcaid L, Qvortrup C, Yde CW, Schmidt AY, Nielsen FC, Willemoe GL, Dam MS, Lassen U, Staal Rohrberg K. Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact. Acta Oncol. 2022 Dec;61(12):1499-1506. doi: 10.1080/0284186X.2022.2156809. Epub 2022 Dec 18.
PMID: 36529989DERIVEDTuxen IV, Rohrberg KS, Oestrup O, Ahlborn LB, Schmidt AY, Spanggaard I, Hasselby JP, Santoni-Rugiu E, Yde CW, Mau-Sorensen M, Nielsen FC, Lassen U. Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials. Clin Cancer Res. 2019 Feb 15;25(4):1239-1247. doi: 10.1158/1078-0432.CCR-18-1780. Epub 2018 Oct 1.
PMID: 30274980DERIVED
Study Officials
- PRINCIPAL INVESTIGATOR
Ulrik Lassen, MD, PH.D.
Rigshospitalet, Denmark
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- MD, PH.D
Study Record Dates
First Submitted
October 8, 2014
First Posted
November 14, 2014
Study Start
May 1, 2013
Primary Completion
December 1, 2023
Study Completion
December 1, 2023
Last Updated
October 26, 2022
Record last verified: 2022-10